158 related articles for article (PubMed ID: 34231532)
1. Complications of retinopathy of prematurity treatment.
Barnett JM; Hubbard GB
Curr Opin Ophthalmol; 2021 Sep; 32(5):475-481. PubMed ID: 34231532
[TBL] [Abstract][Full Text] [Related]
2. Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity.
Sankar MJ; Sankar J; Chandra P
Cochrane Database Syst Rev; 2018 Jan; 1(1):CD009734. PubMed ID: 29308602
[TBL] [Abstract][Full Text] [Related]
3. Retinal Detachment after Treatment of Retinopathy of Prematurity with Laser versus Intravitreal Anti-Vascular Endothelial Growth Factor.
Barry GP; Yu Y; Ying GS; Tomlinson LA; Lajoie J; Fisher M; Binenbaum G;
Ophthalmology; 2021 Aug; 128(8):1188-1196. PubMed ID: 33387554
[TBL] [Abstract][Full Text] [Related]
4. Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial.
Geloneck MM; Chuang AZ; Clark WL; Hunt MG; Norman AA; Packwood EA; Tawansy KA; Mintz-Hittner HA;
JAMA Ophthalmol; 2014 Nov; 132(11):1327-33. PubMed ID: 25103848
[TBL] [Abstract][Full Text] [Related]
5. Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity.
Sankar MJ; Sankar J; Mehta M; Bhat V; Srinivasan R
Cochrane Database Syst Rev; 2016; 2():CD009734. PubMed ID: 26932750
[TBL] [Abstract][Full Text] [Related]
6. Antivascular endothelial growth factor in the treatment of retinopathy of prematurity.
Patel JR; Ranjan SS; Wasserman BN
Curr Opin Ophthalmol; 2016 Sep; 27(5):387-92. PubMed ID: 27206263
[TBL] [Abstract][Full Text] [Related]
7. Comparison of adverse events between intravitreal anti-VEGF and laser photocoagulation for treatment-requiring retinopathy of prematurity: a systematic review.
Tsiropoulos GN; Seliniotaki AK; Haidich AB; Ziakas N; Mataftsi A
Int Ophthalmol; 2023 Mar; 43(3):1027-1062. PubMed ID: 36214992
[TBL] [Abstract][Full Text] [Related]
8. Effect of Intravitreal Aflibercept vs Laser Photocoagulation on Treatment Success of Retinopathy of Prematurity: The FIREFLEYE Randomized Clinical Trial.
Stahl A; Sukgen EA; Wu WC; Lepore D; Nakanishi H; Mazela J; Moshfeghi DM; Vitti R; Athanikar A; Chu K; Iveli P; Zhao F; Schmelter T; Leal S; Köfüncü E; Azuma N;
JAMA; 2022 Jul; 328(4):348-359. PubMed ID: 35881122
[TBL] [Abstract][Full Text] [Related]
9. Description and management of retinopathy of prematurity reactivation after intravitreal antivascular endothelial growth factor therapy.
Valikodath NG; Chiang MF; Chan RVP
Curr Opin Ophthalmol; 2021 Sep; 32(5):468-474. PubMed ID: 34397577
[TBL] [Abstract][Full Text] [Related]
10. Comparison of Bevacizumab, Ranibizumab, and Laser Photocoagulation in the Treatment of Retinopathy of Prematurity in Turkey.
Gunay M; Sukgen EA; Celik G; Kocluk Y
Curr Eye Res; 2017 Mar; 42(3):462-469. PubMed ID: 27420302
[TBL] [Abstract][Full Text] [Related]
11. Comparison of efficacy between anti-vascular endothelial growth factor (VEGF) and laser treatment in Type-1 and threshold retinopathy of prematurity (ROP).
Li Z; Zhang Y; Liao Y; Zeng R; Zeng P; Lan Y
BMC Ophthalmol; 2018 Jan; 18(1):19. PubMed ID: 29378530
[TBL] [Abstract][Full Text] [Related]
12. Ocular complications following treatment in the Postnatal Growth and Retinopathy of Prematurity (G-ROP) Study.
Morrison D; Shaffer J; Ying GS; Binenbaum G;
J AAPOS; 2018 Apr; 22(2):128-133. PubMed ID: 29548840
[TBL] [Abstract][Full Text] [Related]
13. The role of anti-vascular endothelial growth factor in treatment of retinopathy of prematurity-a current review.
Chow SC; Lam PY; Lam WC; Fung NSK
Eye (Lond); 2022 Aug; 36(8):1532-1545. PubMed ID: 35017699
[TBL] [Abstract][Full Text] [Related]
14. Outcomes after Intravitreal Bevacizumab versus Laser Photocoagulation for Retinopathy of Prematurity: A 5-Year Retrospective Analysis.
Hwang CK; Hubbard GB; Hutchinson AK; Lambert SR
Ophthalmology; 2015 May; 122(5):1008-15. PubMed ID: 25687024
[TBL] [Abstract][Full Text] [Related]
15. [Effects of intravitreal pegaptanib or bevacizumab and laser in treatment of threshold retinopathy of prematurity in zone I and posterior zone II--four years results].
Autrata R; Senková K; Holousová M; Krejcírová I; Dolezel Z; Borek I
Cesk Slov Oftalmol; 2012 Feb; 68(1):29-36. PubMed ID: 22679695
[TBL] [Abstract][Full Text] [Related]
16. Characteristics of 'sawtooth shunt' following anti-vascular endothelial growth factor for aggressive posterior retinopathy of prematurity.
Padhi TR; Das T; Kaur P; Sutar S; Khalsa A; Modi R; Ali H; Pradhan L; Jalali S
Int Ophthalmol; 2020 Apr; 40(4):1007-1015. PubMed ID: 31925658
[TBL] [Abstract][Full Text] [Related]
17. Anti-Vascular Endothelial Growth Factor Preparations in the Treatment of Retinopathy of Prematurity: Balancing Risks and Benefits.
Chawla D; Darlow BA
Indian Pediatr; 2016 Nov; 53 Suppl 2():S129-S136. PubMed ID: 27915321
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of intravitreal bevacizumab for zone-II retinopathy of prematurity.
Karkhaneh R; Khodabande A; Riazi-Eafahani M; Roohipoor R; Ghassemi F; Imani M; Dastjani Farahani A; Ebrahimi Adib N; Torabi H
Acta Ophthalmol; 2016 Sep; 94(6):e417-20. PubMed ID: 27009449
[TBL] [Abstract][Full Text] [Related]
19. A Dosing Study of Bevacizumab for Retinopathy of Prematurity: Late Recurrences and Additional Treatments.
Wallace DK; Dean TW; Hartnett ME; Kong L; Smith LE; Hubbard GB; McGregor ML; Jordan CO; Mantagos IS; Bell EF; Kraker RT;
Ophthalmology; 2018 Dec; 125(12):1961-1966. PubMed ID: 29887334
[TBL] [Abstract][Full Text] [Related]
20. Factors associated with refractive outcome in children treated with bevacizumab for retinopathy of prematurity: the importance of retinal vascularization.
Bayramoglu SE; Sayin N
Int Ophthalmol; 2022 Oct; 42(10):3199-3210. PubMed ID: 35579771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]